Celanese has entered into an agreement with Glaukos to supply the VitalDose drug delivery platform for Glaukos’ iDose TR, according to a press release.
The iDose TR is a microinvasive intraocular implant designed to continuously deliver a travoprost formulation to lower IOP in those with primary open-angle glaucoma or ocular hypertension. VitalDose has the potential to help provide continuous dosing, which can reduce issues with patient compliance and adherence.
According to the release, VitalDose provides “reliable, controlled-release performance and has a long history of use in